stoxline Quote Chart Rank Option Currency Glossary
  
Madrigal Pharmaceuticals, Inc. (MDGL)
229.58  -5.27 (-2.24%)    05-24 16:00
Open: 234.81
High: 235.24
Volume: 374,471
  
Pre. Close: 234.85
Low: 228.73
Market Cap: 4,893(M)
Technical analysis
2024-05-27 4:47:24 PM
Short term     
Mid term     
Targets 6-month :  292.23 1-year :  341.32
Resists First :  250.19 Second :  292.23
Pivot price 221.27
Supports First :  212.37 Second :  189
MAs MA(5) :  234.81 MA(20) :  219.03
MA(100) :  231.32 MA(250) :  208.2
MACD MACD :  1.9 Signal :  -1.5
%K %D K(14,3) :  66 D(3) :  76.6
RSI RSI(14): 53.6
52-week High :  299.98 Low :  119.76
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ MDGL ] has closed below upper band by 32.8%. Bollinger Bands are 3.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 235.74 - 237.16 237.16 - 238.21
Low: 225.37 - 227.24 227.24 - 228.62
Close: 227.14 - 229.88 229.88 - 231.92
Company Description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Headline News

Mon, 27 May 2024
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Sat, 25 May 2024
Robert E. Waltermire Sells 1036 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock - Defense World

Fri, 24 May 2024
Insider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, Chief Pharmaceutical Development Officer Robert ... - GuruFocus.com

Fri, 24 May 2024
Madrigal Pharmaceuticals senior VP sells over $239k in company stock - Investing.com

Wed, 08 May 2024
When Will Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Turn A Profit? - Simply Wall St

Wed, 08 May 2024
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 21 (M)
Shares Float 13 (M)
Held by Insiders 15.3 (%)
Held by Institutions 93.8 (%)
Shares Short 3,980 (K)
Shares Short P.Month 3,360 (K)
Stock Financials
EPS -23.13
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 41.13
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -40.2 %
Return on Equity (ttm) -88.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -21.29
Qtrly Earnings Growth 0 %
Operating Cash Flow -389 (M)
Levered Free Cash Flow -230 (M)
Stock Valuations
PE Ratio -9.93
PEG Ratio 0
Price to Book value 5.58
Price to Sales 0
Price to Cash Flow -12.57
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android